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PRECIS 
Preliminary results from NPC-0501 Trial showed that the benefit of changing from 
concurrent-adjuvant to induction-concurrent sequence remains uncertain; replacing 
fluorouracil by capecitabine warrants further validation in view of convenience, favorable 
toxicity profile and at least comparable efficacy. In concurrence with studies on other head 
and neck cancers, accelerated fractionation is not recommended for locoregionally advanced 
nasopharyngeal carcinoma treated by chemoradiotherapy.  
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BACKGROUND: A current recommendation for locoregionally advanced nasopharyngeal 
carcinoma (NPC) is conventional-fractionated radiotherapy with concurrent cisplatin plus 
adjuvant cisplatin and fluorouracil (PF). This randomized trial evaluates the therapeutic 
benefit by changing to induction-concurrent sequence, oral capecitabine (X) and/or 
accelerated fractionation. METHODS: Patients with stage III-IVB non-keratinizing NPC 
were randomly allocated to one of six arms. The protocol was amended in 2009 to permit 
confining randomization to conventional-fractionated arms. The primary endpoint was 
progression-free survival (PFS); secondary endpoints included overall survival and safety. 
RESULTS: A total of 803 patients were accrued (706 randomly allocated to all six arms). 
Comparisons of Induction-PF vs adjuvant-PF did not show significant improvement. 
Unadjusted comparisons of Induction-PX vs adjuvant-PF showed favorable trend in PFS in 
the Conventional-fractionated stratum (P = .045); analyses adjusted for other significant 
factors and fractionation showed significant reduction of progression (hazard ratio 0.54 
[0.36-0.80]) and death (0.42 [0.25-0.70]). Unadjusted comparisons of Induction vs Adjuvant 
sequence did not reach statistical significance, but adjusted comparisons showed favorable 
improvement. Comparisons of Induction-PX versus Induction-PF showed less toxicities 
(neutropenia and electrolyte disturbance), unadjusted comparisons of efficacy were 
statistically insignificant, but adjusted analyses showed lower hazard of death (0.57 
[0.34-0.97]). Changing fractionation from Conventional to Accelerated did not achieve any 
benefit, but incurred higher toxicities (acute mucositis and dehydration). CONCLUSIONS: 
Preliminary results showed that the benefit of changing to induction-concurrent sequence 
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remains uncertain; replacing fluorouracil with oral capecitabine warrants further validation; 
accelerated fractionation is not recommended for locoregionally advanced NPC treated with 
chemoradiotherapy. 
 
KEYWORDS: nasopharyngeal carcinoma, randomized controlled trial, chemoradiotherapy, 
capecitabine, accelerated fractionation 
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INTRODUCTION 
Since the first report of significant survival benefits by the Intergroup-0099 Study,
1
 addition 
of concurrent cisplatin plus adjuvant cisplatin and fluorouracil (PF) to 
conventional-fractionated radiotherapy (RT) has become a standard recommendation
 
in 
National Comprehensive Cancer Network (NCCN) practice guideline
2
 for patients with 
locoregionally advanced nasopharyngeal carcinoma (NPC). Three subsequent trials 
confirmed the efficacy of this concurrent-adjuvant strategy.
3-5
 However, distant control 
remains a key problem, more efficacious regimen is needed. 
 The Hong Kong Nasopharyngeal Cancer Study Group initiated this multi-center 
randomized controlled trial to evaluate three promising strategies. The first strategy is to 
change the chemotherapy sequence from concurrent-adjuvant to induction-concurrent. An 
exploratory study
6
 based on patients from the NPC-9901
4
 and NPC-9902
7
 Trials showed that 
the number of adjuvant cycles and the dose of fluorouracil given had significant impact on 
distant control. However, the adjuvant phase is often poorly tolerated. Changing to induction, 
with better tolerance
8
 and upfront use of cytotoxic drug combination, could theoretically be 
more effective for eradicating potent micro-metastases. In addition, this could shrink the 
primary tumor to give wider margin for RT, an advantage that is particularly needed for 
tumors infiltrating/abutting critical neurological structures.
8
 With encouraging results 
extensively reported from Phase II studies since the first report by Rischin et al,
9
 this has 
been included as an option (Category 3 evidence) in NCCN guideline
2
 and (II, B evidence) in 
European guideline.
10  
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Our second strategy is to improve the current PF regimen by replacing fluorouracil 
(given by infusion) with capecitabine (Xeloda, oral preparation manufactured by Roche).  
Besides obvious advantage of convenience,
11
 potential improvement in efficacy and 
safety
12-15
 could be achieved because capecitabine is metabolized to fluorouracil via a 
three-step enzymatic cascade with final conversion mediated by thymidine phosphorylase, an 
enzyme present at significantly increased concentrations in a wide range of solid tumors 
compared with normal tissue; furthermore, uracil analogues may have anti-angiogenic 
effect.
16
  
 NPC-9902 Trial
7
 suggested that combining concurrent-adjuvant chemotherapy with 
accelerated fractionation could improve tumor control for advanced local diseases. However, 
this can only be taken as hypothesis-generating because the trial was terminated early due to 
slow accrual. Our third strategy is to re-evaluate the potential benefit by changing RT 
fractionation from conventional to acceleration. 
 
MATERIALS AND METHODS 
Patients 
Eligible patients had histologically confirmed non-keratinizing (differentiated or 
undifferentiated) NPC by World Health Organization Classification; Stage III-IVB (tumor 
with bony structure, paranasal sinuses [T3], or intracranial extension, cranial nerve, 
hypopharynx, orbit, infratemporal fossa (masticator space) involvement [T4]; cervical lymph 
node metastasis with bilateral involvement [N2], greatest dimension >6 cm [N3a] or 
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extension into supraclavicular fossa [N3b]; and no distant metastasis [M0]) by American 
Joint Committee on Cancer Staging System (6
th
 edition).
16
 Other inclusion criteria were age 
18-69 years, performance status of 2 or lower by the Eastern Cooperative Oncology Group 
System, adequate hematologic and renal functions. The exclusion criteria were pregnancy or 
lactation, history of previous treatment, or prior malignancy. 
 The protocol was approved by the institutional ethics committees of individual 
participating center, and the trial was monitored by an independent Data Monitoring 
Committee. All patients provided written informed consent.  
 All patients were assessed by complete physical examination, fibreoptic 
nasopharyngoscopy, magnetic resonance imaging and/or computed tomography of the 
nasopharyngeal region, chest radiograph, complete blood count, renal and liver function tests, 
and lactate dehydrogenase (LDH). Additional investigations were performed for those with 
suspicious findings or abnormal biochemical profile.  
 
Study Design and Randomization 
Eligible patients were stratified by participating center and stage (III vs IV), and randomly 
allocated in equal proportions to six arms. Blocks of variable size were chosen randomly by 
the designing statistician to ensure both randomness and investigator blinding; sealed 
envelopes for each stratum (defined by center and stage) were sequentially numerated and 
sent to the randomization office in each center, where patient eligibility is confirmed and the 
sealed envelope with the next number in the corresponding stratum is opened to allocate 
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treatment. 
 In accordance with the original protocol (September 2006), eligible patients were 
initially randomized in equal proportions to one of the six arms (Fig. 1). The protocol was 
amended in January 2009 following the recommendation of the independent Data Monitoring 
Committee: individual centers with logistical difficulty to arrange six RT fractions per week 
were allowed to opt out of the accelerated fractionation portion of the trial in order to 
improve accrual. 
 The protocol specified two reporting: a preliminary report after the closure of the 
study (regardless of their significance) and the final report after 5-year follow-up for all 
surviving patients. 
 
Treatment and Assessment 
Patients in all arms were irradiated with megavoltage photons using the same RT technique 
and dose in line with the policy of individual center. A total dose of 70 Gy or greater (66 Gy 
for T1-2a) was given to the gross tumor targets, and 50 Gy or greater to potential sites of 
local infiltration and bilateral cervical lymphatics. Additional boosts (not exceeding 20 Gy) 
could be given to the parapharyngeal space, the primary or nodal sites (when indicated); the 
boost field was confined to the involved site with exclusion of critical structures. The number 
of fractions per week was 5 in the Conventional group, and 6 in the Accelerated group (the 
sixth fraction was given either on Saturday or on a weekday with ≥ 6 hours between 
fractions). 
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 Patients in all arms were given concurrent cisplatin 100 mg/m
2
 intravenous infusion 
(IVI) every 21 days for 2-3 cycles (depending on overall RT time). Patients allocated to the 
Adjuvant-PF group were given adjuvant cisplatin 80 mg/m
2
 IVI + fluorouracil 1000 
mg/m
2
/day IVI for 96 hours every 28 days for 3 cycles. Patients allocated to the Induction-PF 
group were given induction cisplatin 100 mg/m
2
 IVI + fluorouracil 1000 mg/m
2
/day IVI for 
120 hours every 21 days for 3 cycles. For patients allocated to the Induction-PX group, 
fluorouracil was replaced by capecitabine 2000 mg/m
2
/day orally for 14 days per cycle. Dose 
modifications were permitted according to protocol-specified criteria.  
 The intended total dose of chemotherapy per treatment arms are as follows: 
Arm 1A: Cisplatin 540mg/m
2
,
 
5-Fluorouracil 12,000 mg/m
2
 
Arm 1B: Cisplatin 440mg/m
2
,
 
5-Fluorouracil 12,000 mg/m
2
 
Arm 2A: Cisplatin 600mg/m
2
, 5-Fluorouracil 15,000 mg/m
2
 
Arm 2B: Cisplatin 500mg/m
2
, 5-Fluorouracil 15,000 mg/m
2
 
Arm 3A : Cisplatin 600mg/m
2
, Capecitabine 84,000 mg/m
2
 
Arm 3B : Cisplatin 500mg/m
2
, Capecitabine 84,000 mg/m
2
 
 The first assessment of tumor response was performed 6 weeks to 16 weeks after 
completion of RT. All patients were assessed by complete physical examination and 
fiberoptic nasopharyngoscopy. Further investigations with computed tomography/MRI or 
other tests were arranged when indicated (regular imaging assessment was not routinely 
performed due to limitation of resources). Persistent primary or nodal disease at 16 weeks 
after completion of RT was taken as locoregional failure. Persistent disease and relapse were 
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treated with the policy of individual center. Common Toxicity Criteria for Adverse Events 
version 3.0 was used to gauge toxicities (both acute and late).  
 
Statistical Analysis 
All analyses were performed on an intent-to-treat basis, the tests are two-sided, and events for 
actuarial rates were measured from the date of randomization as the starting date. For the 
preliminary report, the primary endpoint is progression-free survival (PFS, time to first 
failure at any site or death due to any cause). The standard group is the Adjuvant-PF group 
with Conventional-fractionated RT, 5-year results were estimated from previous reports.
4, 5,7,18 
The following sets of hypotheses and assumptions are used for power calculation: 
H0:   The null hypotheses of no difference in treatment efficacy: 5-year PFS is 65% in all 
groups;  
HA:   The alternative hypotheses of treatment efficacy: the 5-year PFS is 65% in the 
standard group and 75% in the experimental groups.  
For detecting this 10% difference in PFS with alpha error of 0.05 and 80% power, the target 
accrual is 798 patients.   
 Secondary endpoints for treatment efficacy in the preliminary report included overall 
survival (OS, time to death due to any cause). Secondary endpoints for safety included major 
toxicities (grade 3 or above) both acute (incidence rates compared by Chi-square) and late 
(time to toxicities compared by log-rank test). 
 Primary comparisons include comparisons of each induction regimen to the adjuvant 
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regimen (Induction-PF vs Adjuvant-PF, Induction-PX vs Adjuvant-PF) and fractionation 
(Accelerated vs Conventional). Secondary comparisons include comparisons of sequence 
(Induction vs Adjuvant) and induction regimens (Induction-PX vs Induction-PF group).  
 Stratified log-rank test was used: comparisons on regimen groups and sequence were 
stratified by fractionation (Accelerated, Conventional), while comparisons on fractionation 
were stratified by regimen groups (Adjuvant-PF, Induction-PF, Induction-PX). In addition, 
multivariate analyses by Cox regression were performed to evaluate independent significance 
of intervention and other potential prognostic factors. 
 
RESULTS 
Basic Characteristics and Radiotherapy 
From September 2006 to 2012, 803 eligible patients from seven participating centers were 
randomly allocated (Fig 1): 706 patients were randomly allocated to all six arms and 97 
patients to Conventional-fractionated arms only. All except one patient with lost record were 
analyzed. 
 The six treatment arms were well balanced in all patient characteristics, tumor factors, 
RT technique and total dose (Table 1). The median duration of follow-up for the whole series 
was 3.3 years (range 0.1-7.1). 
  
Chemotherapy Tolerance 
The number of concurrent cycles varied with both chemotherapy sequence and fractionation 
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(Table 2). As the mean overall RT time for the Accelerated group was shorter than the 
Conventional group (mean 40 vs 47 days), the proportion of patients with 3 concurrent cycles 
was correspondingly lower (11% vs 43%, P < .001), but the proportion with at least 2 
concurrent cycles was identical (92% in both). Significantly higher proportion of patients in 
the Induction group completed 3 non-concurrent cycles as compared with the Adjuvant group 
(88% vs 64%, P < .001), but lower proportion had ≥2 concurrent cycles (90% vs 95%, P 
= .009). There were no significant differences between the two induction regimens (PX vs PF) 
in the mean number of cycles given during both phases (P > .47). 
 
Efficacy 
In this preliminary study, the core analyses on efficacy were based on the 706 patients 
randomized to all six arms as planned in the original study design: 171 patients had 
progression (failure or death) and 116 had death due to any cause. Table 3 summarized the 
comparisons of PFS and OS rates by stratified log-rank test; Fig. 2-3 showed the actuarial 
PFS curves for each stratum. Univariate analyses showed significant impact by other factors 
(including stage, LDH, age, sex, RT technique and center), the independent effect of 
intervention methods were analyzed by Cox regression with adjustment for these factors 
(Table 4). 
 Comparisons of regimen Induction-PF vs Adjuvant-PF did not show statistically 
significant improvement. Unadjusted comparisons of Induction-PX vs Adjuvant-PF showed 
favorable trend in PFS in the Conventional stratum (Fig. 2A, 81% vs 75% at 3-year, P = .045), 
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but insignificant differences in the Accelerated stratum. When adjusted for other significant 
factors and fractionation, Induction-PX achieved significant reduction in hazard of 
progression (hazard ratio [HR] 0.54, [95% confidence interval 0.36-0.80], P = .002) and 
death (HR 0.42 [0.25-0.70], P = .001). When the two induction regimens were combined for 
evaluation of Induction vs Adjuvant sequence, unadjusted comparisons did not reach 
statistical significance, but adjusted comparisons showed reduction in hazard of progression 
(HR 0.67, [0.48-0.93], P = .016) and death (HR 0.57 [0.39-0.86], P = .006).   
 For comparisons of capecitabine vs fluorouracil, unadjusted comparisons of 
Induction-PX vs Induction-PF did not show significant improvement, but adjusted analyses 
showed lower hazard of death (HR 0.57 [0.34-0.97], P = .037). Finally, all comparisons (both 
adjusted and unadjusted) of fractionation Accelerated vs Conventional did not show any 
benefit. 
 
Safety 
Table 5 summarizes major toxicities grade 3 or above. The Induction group had higher 
incidence of chemotherapy-related toxicities including neutropenia, thrombocytopenia, renal 
impairment and peripheral neuropathy, but less weight loss than the Adjuvant group. 
Comparison of the two induction regimens showed that induction-PX had less neutropenia 
and electrolyte disturbance. The Accelerated group had significantly higher incidence of 
acute mucositis and dehydration than the Conventional group.  
 Majorities of toxicities are uneventful; treatment mortality for the whole series was 
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1.2%. There were no significant differences in late toxicities and non-cancer deaths among 
the groups. 
 
DISCUSSION 
There is little controversy that addition of chemotherapy could achieve significant survival 
benefit for patients with locoregionally advanced NPC, and concurrent sequence is the most 
efficacious for combining with RT.
19
 There are differences of opinion as to whether  
concurrent alone or concurrent-adjuvant chemotherapy should be recommended. Preliminary 
results from a randomized trial by Chen et al.
20
 comparing concurrent-adjuvant vs concurrent 
alone chemoradiotherapy showed no statistically significant differences in 2-year results: HR 
for failure-free survival was 0.74 (0.49-1.10), P = .13. However, it must be cautioned that the 
follow-up was too short for definitive confirmation. Data from the second patient-data based 
meta-analysis by MAC-NPC Collaborative Group
21
 showed that both groups achieved 
significant benefit in OS: the concurrent-adjuvant group showed robust long-term results (HR 
= 0.65 [0.56-0.76], with 5/6 comparisons individually significant); the corresponding results 
in the concurrent alone group was HR = 0.80 [0.70-0.93] (2/7 comparisons individually 
significant, the greatest benefit was observed in a trial aimed for Stage II). 
Concurrent-adjuvant chemotherapy remains a recommendation with Level 1A evidence; the 
use of this sequence as the standard arm in the current trial is relevant. 
 All the reported trials on Concurrent-adjuvant chemotherapy used concurrent cisplatin 
and adjuvant PF; hence PF is used as the standard non-concurrent chemotherapy in the 
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current trial. Unlike other head and neck cancers, no trial has yet been conducted on 
non-keratinizing NPC to evaluate the benefit of adding taxane or compare the efficacy of 
taxane versus fluorouracil. As our previous exploratory study on NPC-9901 and NPC-9902 
Trials
6
 showed dose-dependent effect of fluorouracil on distant failure, we focus on exploring 
for better uracil agent.  
 As explained in the Introduction, the current trial is designed to evaluate three 
potential strategies: induction-concurrent sequence, use of capecitabine, and accelerated 
fractionation. In concurrence with a review
18
 of reported studies, patients treated with 
induction-concurrent regimens had excellent tolerance in the non-concurrent phase, but 
decreased tolerance in the concurrent phase. Acceleration further affected the proportion of 
patients with 3 concurrent cycles. Such interacting variations (Table 2) may affect the 
ultimate efficacy of the induction and the acceleration strategies. 
 Regarding the change to induction-concurrent sequence, there are five randomized 
studies by other groups, all used concurrent alone chemotherapy as the standard arm. Despite 
the encouraging results of single-arm studies, three reported randomized studies showed 
conflicting results. Hui et al.
22
 (adding induction cisplatin and docetaxel, n = 65) showed 
significantly better 3-year OS, but both Fountzilas et al.
23
 (adding cisplatin, epirubicin and 
paclitaxel, n = 141) and Tan et al.
24
 (adding carboplatin, gemcitabine and paclitaxel, n = 172) 
did not achieve OS benefit. Two trials are still on-going.  
 Preliminary results from the current trial (Tables 3 and 4, Fig. 2) showed that 
changing the sequence per se, as shown by comparison of Induction-PF versus Adjuvant-PF, 
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did not achieve statistically significant improvement in efficacy. More encouraging results 
were achieved by changing both the sequence and the induction regimen: unadjusted 
comparison of induction-PX versus Adjuvant-PF showed favorable trend in PFS when given 
with Conventional-fractionated RT (P = .045). Multivariate analyses further showed that 
when adjusted for other significant factors and fractionation, PX group had significantly 
lower hazard in progression (P = .002) and death (P = .001). When the two induction groups 
were combined for evaluation of sequence Induction versus Adjuvant, unadjusted 
comparisons did not reach statistical significance, but adjusted analyses also showed lower 
hazard in progression (P = .016) and death (P = .006).  
 The change from fluorouracil to capecitabine has been extensively studied in other 
solid cancers. Studies comparing capecitabine versus fluorouracil in gastrointestinal cancers 
consistently confirmed that capecitabine is a favorable alternative with at least equivalent 
efficacy, lower toxicities and better patient acceptance.
10-14
 However the conclusion on 
survival benefit is less definitive. Two large trials on metastatic colorectal cancer
12,13
 showed 
superior response rates, but only equivalent PFS and OS. The X-ACT Trial on adjuvant 
therapy for colon cancer
14
 showed signiﬁcant survival beneﬁt on preplanned multivariate 
analyses, but only borderline benefit on unadjusted comparisons. A meta-analysis comparing 
capecitabine- versus fluorouracil-containing chemotherapy for colorectal and gastric 
cancers
15
 showed that unadjusted HR for OS was 0·94 (P = ·049). 
 Promising efficacy of capecitabine has been reported in a phase II study
25 
on patients 
with recurrent and metastatic NPC: 24% showed overall response with significant tumor 
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regression after 3 cycles despite heavy pretreatment with cisplatin-based chemotherapy. The 
current trial is the first randomized trial to evaluate this uracil agent for NPC. Replacing 
fluorouracil (given by intravenous infusion) by capecitabine (given orally) is obviously more 
convenient and welcomed by patients. In addition, this regimen incurred less neutropenia and 
electrolyte disturbance (Table 5). In terms of efficacy, unadjusted comparison of 
Induction-PX versus Induction-PF did not show significant difference, but adjusted analysis 
showed that Induction-PX had lower hazard in death (P = .038).  
 Regarding the change to accelerated fractionation, a meta-analysis
26
 showed that 
altered fractionation, particularly hyper-fractionation, can improve survival. However, both 
the GORTEC 99-02 trial
27
 and the RTOG-0129 Study
28
 showed that acceleration is not 
beneficial for patients with concurrent chemoradiotherapy. It should be noted that all these 
studies only focused on other head and neck cancers. The only trial that specifically focused 
on NPC is the NPC-9902 Trial,
7
 which in contrast suggested that acceleration combined with 
concurrent-adjuvant chemoradiotherapy could further improve the failure-free rate for 
T3-4N0-1 disease. However, it must be cautioned that this finding can only be taken as 
hypothesis-generating as the trial was terminated early due to slow accrual, the sample size 
(189 patients) is smaller than the planned target, possibility of subtle biases and chance 
findings cannot be totally excluded.  
 The current trial is the only trial that attempted to confirm this potential strategy. With 
shorter overall RT time, the proportion of patients with 3 concurrent cycles was inevitably 
low in the Accelerated group. With further lowering of tolerance by induction chemotherapy, 
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even the proportion with ≥2 concurrent cycles was affected. In concurrence with trials
27,28
 on 
other head and neck cancers, the current finding showed that acceleration did not improve 
efficacy (Tables 3 and 4, Fig. 3). In addition, acceleration incurred significantly higher 
incidence of acute mucositis and dehydration (Table 5). Together with the logistic difficulty 
for arranging six fractions per week, acceleration is not recommended for patients treated 
with chemoradiotherapy, particularly those with induction-concurrent regimens. 
 The current NPC-0501 Trial is a trial with largest sample size for NPC (802 evaluable 
patients), however, the trial is possibly still under-powered. A major weakness is that the trial 
design is too complex with inclusion of multiple arms and strata. This is further complicated 
by the change in protocol after the first interim analysis allowing centers with logistical 
difficulty to opt out of the Accelerated arms. To be pertinent, all comparisons on efficacy 
related to fractionation were based only on the 706 patients randomly assigned to all six arms. 
Another point that may further lead to difficulty in proving statistical difference is that 90% 
of patients in the current trial were irradiated with modern intensity-modulated technique; the 
magnitude of benefit contributed by chemotherapy is likely to be lower than past series 
irradiated with less optimal techniques. Lastly, the median follow-up for this preliminary 
analysis is 3.3 years; longer observation is needed to confirm the long-term therapeutic ratio. 
Nonetheless, the current findings provide valuable data for guiding clinical practice and 
future trials. 
 In conclusion, our preliminary results showed that the benefit of changing to 
induction-concurrent sequence remains uncertain; the Induction-PF regimen
 
did not achieve 
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statistical significant improvement in efficacy. Changing both the sequence and regimen to 
Induction-PX achieved more favorable trends in efficacy. In view of convenience, favorable 
toxicity profile and at least comparable efficacy, replacing fluorouracil with capecitabine 
warrants further validation. Accelerated fractionation is not recommended for NPC patients 
treated by chemoradiotherapy. 
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TABLE 1. Basic Characteristics and Radiotherapy of the Whole Series (n = 802) 
 Arm 1A 
(n=160) 
Arm 2A 
(n=161) 
Arm 3A 
(n = 165) 
Arm 1B 
(n=104) 
Arm 2B 
(n = 110) 
Arm 3B 
(n = 102) 
Fractionation Conventional Conventional Conventional Accelerated Accelerated Accelerated 
Regimen Adjuvant-PF Induction-PF Induction-PX Adjuvant-PF Induction-PF Induction-PX 
Patient       
Age: mean (SD) years 48 (9) 48 (9) 48 (9) 49 (8) 48 (10) 49 (9) 
Sex - Male 117 (73%) 116 (72%) 133 (81%) 85 (82%) 84 (76%) 78 (76%) 
Performance status       
   0 116 (73%) 106 (66%) 112 (68%) 70 (67%) 67 (61%) 65 (64%) 
   1 43 (27%) 54 (34%) 53 (32%) 33 (32%) 42 (38%) 36 (35%) 
   2 1 (0.6%) 1 (0.6%) 0 (0%) 1 (1.0%) 1 (0.9%) 1 (1.0%) 
Tumor factor       
Staging method       
MRI ± CT 155 (97%) 156 (97%) 158 (96%) 100 (96%) 104 (95%) 102 (100%) 
   CT alone 5 (3%) 5 (3%) 7 (4%) 4 (4%) 6 (5%) 0 (0%) 
T-classification       
T1-2 24 (15%) 33 (20%) 35 (21%) 28 (27%) 26 (24%) 21 (21%) 
   T3 113 (71%) 105 (65%) 103 (62%) 60 (58%) 66 (60%) 61 (60%) 
   T4 23 (14%) 23 (14%) 27 (16%) 16 (15%) 18 (16%) 20 (20%) 
N-classification       
   N0-1 58 (36%) 46 (29%) 37 (22%) 25 (24%) 25 (23%) 25 (25%) 
   N2 77 (48%) 92 (57%) 104 (63%) 61 (59%) 67 (61%) 58 (57%) 
   N3 25 (16%) 23 (14%) 24 (15%) 18 (17%) 18 (16%) 19 (19%) 
Stage-group       
III 114 (71%) 118 (73%) 117 (71%) 74 (71%) 76 (69%) 67 (66%) 
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TABLE 1. Continued. 
Stage-group 
   IVA - IVB 46 (29%) 43 (27%) 48 (29%) 30 (29%) 34 (31%) 35 (34%) 
LDH: mean (SD) iu/L 226 (79) 237 (115) 236 (93) 236 (94) 244 (91) 252 (126) 
Radiotherapy       
Technique       
    2DRT 3 (2%) 5 (3%) 5 (3%) 7 (7%) 2 (2%) 2 (2%) 
    3DRT 6 (4%) 2 (1%) 2 (1%) 3 (3%) 0 (0%) 4 (4%) 
    IMRT 148 (93%) 152 (94%) 154 (93%) 94 (90%) 104 (95%) 94 (92%) 
Total Dose: mean (SD) Gy 69.7 (2.2) 69.6 (3.2) 69.9 (1.7) 69.6 (1.7) 69.3 (5.8) 69.6 (1.9) 
Overall time: mean (SD) day 47 (2.7) 47 (3.0) 47 (2.8) 42 (3.3) 41 (4.4) 41 (3.1) 
Abbreviations: SD, standard deviation; P, cisplatin; F, fluorouracil; X, capecitabine; MRI, magnetic resonance imaging; CT, computed tomography; LDH, lactate 
dehydrogenase; 2DRT, 2-dimensional; 3DRT, 3-dimensional conformal; IMRT, intensity-modulated radiotherapy technique. 
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TABLE 2. Tolerance to Chemotherapy 
Chemotherapy Conventional Fractionation Accelerated Fractionation 
 Adjuvant-PF 
(Arm 1A) 
Induction-PF 
(Arm 2A) 
Induction-PX 
(Arm 3A) 
Adjuvant-PF 
(Arm 1B) 
Induction-PF 
(Arm 2B) 
Induction-PX 
(Arm 3B) 
Concurrent       
  None 3% 7% 5% 0 3% 5% 
  1 cycle 3% 3% 4% 3% 6% 7% 
  2 cycles 40% 49% 58% 75% 85% 83% 
  3 cycles 55% 40% 33% 22% 6% 5% 
Non-Concurrent      
  None 19% 1% 1% 17% 1% 0% 
  1 cycle 8% 6% 7% 12% 8% 3% 
  2 cycles 8% 4% 7% 8% 0 9% 
  3 cycles 65% 89% 85% 63% 91% 88% 
Abbreviations: P, cisplatin; F, fluorouracil; X, capecitabine. 
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TABLE 3. Efficacy – Tumor Control Rates and Stratified Comparisons 
Factor Strata Progression-Free 
Survival 
Overall 
Survival 
Actuarial Rate at 3-year    
  Arm 1A  75% 83% 
  Arm 2A  79% 85% 
  Arm 3A  81% 91% 
  Arm 1B  79% 87% 
  Arm 2B  77% 90%  
  Arm 3B  76% 88% 
  Arm 2-3A  80% 88% 
  Arm 2-3B  76% 89% 
P Value on Comparison by Stratified Log Rank Test  
  Regimen group    
    Induction-PF vs Adjuvant PF Conventional (Arm 2A vs 1A) .30 .30 
Accelerated (Arm 2B vs 1B) .75 .73 
Overall .33 .33 
    Induction-PX vs Adjuvant PF Conventional (Arm 3A vs 1A) .045 .12 
Accelerated (Arm 3B vs 1B) .66 .24 
Overall (Arms 3A-B vs 1A-B) .079 .055 
    Induction-PX vs Induction-PF Conventional (Arm 3A vs 2A) .34 .61 
Accelerated (Arm 3B vs 2B) .90 .34 
Overall .44 .30 
  Sequence    
    Induction vs Adjuvant Conventional (Arms 2-3A vs 1A) .073 .12 
 Accelerated (Arms 2-3B vs 1B) .66 .39 
 Overall .11 .089 
  Fractionation    
    Accelerated vs Conventional Adjuvant-PF (Arm 1B vs 1A) .68 .96 
 Induction-PF (Arm 2B vs 2A) .84 .44 
 Induction-PX (Arm 3B vs 3A) .31 .81 
 Overall .68 .55 
Abbreviations: P, cisplatin; F, fluorouracil; X, capecitabine. 
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TABLE 4. Multivariate Analyses on Independent Significance of Experimental Intervention on Tumor Control: 
Hazard Ratio (95% Confidence Interval) and P Value 
 Progression-Free Survival Overall Survival 
Part I: Regimen Groups and Fractionation in Patients Randomized to All Six Arms (n = 706) 
Regimen Groups .009 .003 
  Induction-PF vs Adjuvant-PF 0.82 (0.57-1.19) 
.29 
0.76 (0.48-1.19) 
.23 
  Induction-PX vs Adjuvant-PF 0.54 (0.36-0.80) 
.002 
0.42 (0.25-0.70) 
.001 
Fractionation: Acceleration vs Conventional 1.13 (0.82-1.54) 
.46 
1.11 (0.75-1.62) 
.61 
Part II: Chemotherapy Sequence and Fractionation in Patients Randomized to All Six Arms (n = 706) 
Sequence: Induction vs Adjuvant 0.67 (0.48-0.93) 
.016 
0.57 (0.39-0.86) 
.006 
Fractionation: Acceleration vs Conventional 1.14 (0.83-1.56) 
.41 
1.12 (0.76-1.64) 
.57 
Part III: Regimen and Fractionation in Patients Randomized to Induction Arms (n = 473) 
Regimen: Induction-PX vs Induction -PF 0.67 (0.44-1.02) 
.059 
0.57 (0.34-0.97) 
.038 
Fractionation: Acceleration vs Conventional 1.34 (0.90-2.01) 
.16 
1.31 (0.80-2.18) 
.30 
The above analyses were adjusted for other significant covariates including stage, lactic dehydrogenase, 
radiotherapy technique, center, gender and age. 
Abbreviations: P, cisplatin; F, fluorouracil; X, capecitabine. 
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TABLE 5. Safety – Major Toxicity (Grade 3 or Above) 
 Regimen group Sequence Fractionation 
 Induction-PX vs Induction-PF 
vs Adjuvant-PF 
Induction 
vs Adjuvant 
Accelerated  
vs Conventional 
Acute Toxicity (grade ≥3): cumulative rate % 
Concurrent phase    
Mucositis (radiation-induced) 30% vs 33% vs 32% 31% vs 32% 38%
1
 vs 27% 
Dermatitis (radiation-induced) 3% vs 4% vs 3% 3% vs 3% 3% vs 4% 
Dysphagia 8% vs 5% vs 6% 7% vs 6% 8% vs 6% 
Dehydration 3% vs 3% vs 3% 3% vs 3% 4%1 vs 2% 
Neutropenia 6%
1
 vs 4%
1,2
 vs 8% 5%
1
 vs 8% 4% vs 8% 
Anemia 8% vs 8% vs 1% 8% vs 1% 5% vs 6% 
Thrombocytopenia 4%
1
 vs 2% vs 0% 3%
1
 vs 0% 2% vs 2% 
Infection 3% vs 2% vs 4% 2% vs 4% 4% vs 3% 
Vomiting 2% vs 2% vs 9% 2% vs 9% 4% vs 5% 
Gastrointestinal  1% vs 0.4% vs 2% 0.7% vs 2% 2% vs 0.8% 
Renal impairment 3% vs 3%1 vs 1% 3%1 vs 1% 3% vs 2% 
Electrolyte disturbance  2% vs 2%
2
 vs 3% 2% vs 3% 3% vs 2% 
Peripheral neuropathy 0.4%
1
 vs 0%
1
 vs 0% 0.2%
1
 vs 0% 0% vs 0.2% 
Weight loss 2% vs 2% vs 2% 2% vs 2% 2% vs 2% 
Others  0.4% vs 0.4% vs 1.1% 0.4% vs 1.1% 0.6% vs 0.6% 
Any acute toxicity  26%1 vs 26%1 vs 45% 26%1 vs 45% 32% vs 32% 
Sequential phase    
Mucositis (radiation-induced) 4% vs 4% vs 5% 4% vs 5% 7%
1
 vs 3% 
Dermatitis (radiation-induced) 5% vs 3% vs 6% 4% vs 6% 7% vs 4% 
Dysphagia 1% vs 2% vs 1% 2% vs 1% 2% vs 1% 
Dehydration 3% vs 2% vs 1% 3% vs 1% 3%
1
 vs 1% 
Neutropenia 28%
1
 vs 39%
1,2
 vs 13% 33%
1
 vs 13% 31% vs 24% 
Anemia 6% vs 5% vs 8% 5% vs 8% 7% vs 6% 
Thrombocytopenia 5%1 vs 2% vs 2% 3%1 vs 2% 3% vs 3% 
Infection 6% vs 3% vs 3% 5% vs 3% 6% vs 3% 
Vomiting 10% vs 4% vs 1% 7% vs 1% 7% vs 4% 
Gastrointestinal  5% vs 7% vs 4% 6% vs 4% 7% vs 5% 
Renal impairment 3% vs 4%
1
 vs 1% 3%
1
 vs 1% 3% vs 2% 
Electrolyte disturbance  4% vs 7%
2
 vs 3% 5% vs 3% 6% vs 4% 
Peripheral neuropathy 10%1 vs 6%1 vs 2% 8%1 vs 2% 7% vs 6% 
Weight loss 1% vs 2% vs 8% 1% vs 8% 3% vs 4% 
Others  5% vs 3% vs 1% 4% vs 1% 2% vs 3% 
Any acute toxicity  48%
1
 vs 52%
1
 vs 19% 50%
1
 vs 19% 44% vs 37% 
Late Toxicity (grade ≥3): actuarial rate at 3-year 
Central nervous system 0.9% vs 0.8% vs 0.8% 0.9% vs 0.8% 1.0% vs 0.7% 
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Ear toxicity 8% vs 6% vs 8% 7% vs 8% 6% vs 10% 
Soft tissue/bone damage necrosis 1.2% vs 0.4% vs 1.7% 0.8% vs 1.7% 0.4% vs 1.6% 
Others 1.5% vs 0.4% vs 2.0% 0.9% vs 2.0% 2.1% vs 0.6% 
Any late toxicity 10% vs 7% vs 12% 9% vs 12% 8% vs 12% 
Abbreviations: P, cisplatin; F, fluorouracil; X, capecitabine;  
Peripheral neuropathy (sensory and/or motor) irrespective of persistence;  
Ear toxicity (hearing impairment and/or otitis) irrespective of time of onset; 
Central nervous system (temporal lobe necrosis, brainstem damage and/or cranial neuropathy); 
Significantly higher toxicity (P < .05): 
1
Experimental vs standard group, 
2
Induction-PF vs Induction-PX  
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FIGURE LEGENDS 
FIGURE 1. CONSORT diagram of the whole series in NPC-0501 Trial. 
FIGURE 2. Comparison of progression-free survival by (A) regimen groups in patients with 
conventional-fractionation; (B) regimen groups in patients with accelerated -fractionation; (C) chemotherapy 
sequence in patients with conventional-fractionation; and (D) chemotherapy sequence in patients with 
accelerated -fractionation. 
FIGURE 3. Comparison of progression-free survival by fractionation (A) adjuvant cisplatin-fluorouracil group; 
(B) induction cisplatin-fluorouracil group; and (C) induction cisplatin-capecitabine group.  
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CONSORT diagram of the whole series in NPC-0501 Trial.  
211x147mm (300 x 300 DPI)  
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Comparison of progression-free survival by (A) regimen groups in patients with conventional-fractionation; 
(B) regimen groups in patients with accelerated -fractionation; (C) chemotherapy sequence in patients with 
conventional-fractionation; and (D) chemotherapy sequence in patients with accelerated -fractionation.  
254x236mm (100 x 100 DPI)  
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Comparison of progression-free survival by fractionation (A) adjuvant cisplatin-fluorouracil group; (B) 
induction cisplatin-fluorouracil group; and (C) induction cisplatin-capecitabine group.  
380x118mm (100 x 100 DPI)  
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